A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

This was the stock's third consecutive day of losses.

Returns for PFE stock were 67% in 2021, -10% in 2022, and -41% in 2023. In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, is considerably less volatile.

The Zacks Consensus Estimate for PFE’s 2025 sales implies a year-over-year decrease of 0.6% and 1%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 60 days.

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the February 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.